These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1037 related items for PubMed ID: 27768242

  • 21. Real-world use of apremilast for patients with psoriasis in Japan.
    Kishimoto M, Komine M, Hioki T, Kamiya K, Sugai J, Ohtsuki M.
    J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
    [Abstract] [Full Text] [Related]

  • 22. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
    Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, Crowley J.
    J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
    [Abstract] [Full Text] [Related]

  • 23. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J.
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study.
    Ighani A, Georgakopoulos JR, Zhou LL, Walsh S, Shear N, Yeung J.
    J Cutan Med Surg; 2018 Nov; 22(3):290-296. PubMed ID: 29373924
    [Abstract] [Full Text] [Related]

  • 25. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
    Bissonnette R, Pariser DM, Wasel NR, Goncalves J, Day RM, Chen R, Sebastian M.
    J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
    [Abstract] [Full Text] [Related]

  • 26. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
    Papadavid E, Rompoti N, Theodoropoulos K, Kokkalis G, Rigopoulos D.
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
    [Abstract] [Full Text] [Related]

  • 27. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
    Stein Gold LF, Bagel J, Tyring SK, Hong HC, Pavlovsky L, Vender R, Pinter A, Reich A, Drogaris L, Wu T, Patel M, Soliman AM, Photowala H, Stakias V, Richter S, Papp KA.
    Br J Dermatol; 2023 Oct 25; 189(5):540-552. PubMed ID: 37488811
    [Abstract] [Full Text] [Related]

  • 28. Apremilast for psoriasis treatment.
    Carrascosa JM, Del-Alcazar E.
    G Ital Dermatol Venereol; 2020 Aug 25; 155(4):421-433. PubMed ID: 32545946
    [Abstract] [Full Text] [Related]

  • 29. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.
    Armstrong AW, Betts KA, Sundaram M, Thomason D, Signorovitch JE.
    J Am Acad Dermatol; 2016 Oct 25; 75(4):740-746. PubMed ID: 27476973
    [Abstract] [Full Text] [Related]

  • 30. Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study.
    Bissonnette R, Haydey R, Rosoph LA, Lynde CW, Bukhalo M, Fowler JF, Delorme I, Gagné-Henley A, Gooderham M, Poulin Y, Barber K, Jenkin P, Landells I, Pariser DM.
    J Eur Acad Dermatol Venereol; 2018 Mar 25; 32(3):403-410. PubMed ID: 29055155
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
    Blauvelt A, Papp KA, Griffiths CEM, Puig L, Weisman J, Dutronc Y, Kerr LF, Ilo D, Mallbris L, Augustin M.
    Am J Clin Dermatol; 2017 Apr 25; 18(2):273-280. PubMed ID: 28074446
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial.
    Merola JF, Parish LC, Guenther L, Lynde C, Lacour JP, Staubach P, Cheng S, Paris M, Picard H, Deignan C, Jardon S, Chen M, Papp KA.
    J Am Acad Dermatol; 2024 Mar 25; 90(3):485-493. PubMed ID: 37852306
    [Abstract] [Full Text] [Related]

  • 33. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
    AbuHilal M, Walsh S, Shear N.
    J Cutan Med Surg; 2016 Jul 25; 20(4):313-6. PubMed ID: 26848145
    [Abstract] [Full Text] [Related]

  • 34. Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial.
    Liu LF, Chen JS, Gu J, Xu JH, Jin HZ, Pang XW, Wang G, Yu C, Song ZQ, Guo ZP, Li W, Lai W, Cui PG, Chen M, Fang H, Lyu CZ, Li YZ, Sun Q, Xie HF, Liu XM, Gao XH, Shi YL, Zhao NQ, Zhang W, Zheng M.
    Arch Dermatol Res; 2020 Aug 25; 312(6):437-445. PubMed ID: 31873772
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial.
    Mrowietz U, Barker J, Conrad C, Jullien D, Gisondi P, Flower A, Reddy J, Paris M, Picard H, Jardon S, Augustin M.
    J Eur Acad Dermatol Venereol; 2023 Feb 25; 37(2):348-355. PubMed ID: 36300769
    [Abstract] [Full Text] [Related]

  • 36. Apremilast in psoriasis - a prospective real-world study.
    Vujic I, Herman R, Sanlorenzo M, Posch C, Monshi B, Rappersberger K, Richter L.
    J Eur Acad Dermatol Venereol; 2018 Feb 25; 32(2):254-259. PubMed ID: 28925560
    [Abstract] [Full Text] [Related]

  • 37. Apremilast for the management of moderate to severe plaque psoriasis.
    Vangipuram R, Alikhan A.
    Expert Rev Clin Pharmacol; 2017 Apr 25; 10(4):349-360. PubMed ID: 28276777
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of apremilast monotherapy in moderate-to-severe plaque psoriasis: A systematic review and meta-analysis.
    Aljefri YE, Ghaddaf AA, Alkhunani TA, Alkhamisi TA, Alahmadi RA, Alamri AM, Alraddadi AA.
    Dermatol Ther; 2022 Jul 25; 35(7):e15544. PubMed ID: 35499185
    [Abstract] [Full Text] [Related]

  • 39. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG, Kircik L, Callis Duffin K, Pariser D, Hooper M, Wenkert D, Thompson EH, Yang J, Kricorian G, Koo J.
    J Am Acad Dermatol; 2013 Sep 25; 69(3):385-92. PubMed ID: 23643256
    [Abstract] [Full Text] [Related]

  • 40. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
    Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K, UNCOVER-2 and UNCOVER-3 investigators.
    Lancet; 2015 Aug 08; 386(9993):541-51. PubMed ID: 26072109
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 52.